List of Excipients in Branded Drug SUMAVEL DOSEPRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zogenix Inc	SUMAVEL DOSEPRO	sumatriptan	43376-106	SODIUM CHLORIDE
Zogenix Inc	SUMAVEL DOSEPRO	sumatriptan	43376-106	WATER

Sumavel DosePro Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Sumavel DosePro is a discontinued U.S. needle-free, subcutaneous sumatriptan product built around a simple sterile aqueous formulation and a proprietary single-use injector. Its commercial value was concentrated in the delivery system, not in excipient innovation. The strongest current opportunity is a device-enabled generic or reformulated sumatriptan product that preserves rapid subcutaneous delivery while lowering manufacturing cost, simplifying use, or improving storage stability.

What is Sumavel DosePro and how is it formulated?

Sumavel DosePro was approved by the FDA in 2009 under NDA 022157 for the acute treatment of migraine attacks, with or without aura, and cluster headaches in adults. Each disposable injector delivers 6 mg of sumatriptan subcutaneously in approximately 0.5 mL of solution.[1]

Attribute	Sumavel DosePro
Active ingredient	Sumatriptan succinate
Delivered dose	6 mg sumatriptan base
Route	Subcutaneous
Dosage form	Sterile injectable solution
Volume	Approximately 0.5 mL
Device	Single-use, needle-free injector
Main indication	Acute migraine and cluster headache treatment
NDA	022157
Original sponsor	Zogenix Inc.
FDA approval	2009
Preservative status	Single-dose, preservative-free presentation
Commercial status	U.S. product discontinued

The formulation is a low-complexity aqueous system. The active ingredient is sumatriptan succinate, with sodium chloride for tonicity and water for injection. The product labeling identifies pH adjustment components, including sulfuric acid, in the manufacturing formulation.[1]

The formulation does not depend on a novel polymer, lipid carrier, surfactant system, depot-forming excipient, or sustained-release matrix. The product’s differentiation came from needle-free delivery and rapid administration.

Which excipients are used in Sumavel DosePro?

The principal excipient strategy is:

1. Sodium chloride for isotonicity.
2. Water for injection as the vehicle.
3. Acid or base adjustment to control pH and maintain chemical stability.
4. A single-dose container and injector configuration that eliminates the need for antimicrobial preservatives.

This strategy has several commercial advantages. It limits toxicological burden, simplifies extractables and leachables assessment, reduces formulation-development time, and supports a relatively straightforward sterile manufacturing process.

The main technical constraint is sumatriptan’s need for a stable aqueous environment at an appropriate pH. A developer seeking to change the buffer, salt system, or pH would need to demonstrate equivalent assay, impurity profile, particulate control, osmolality, injection performance, and container-closure stability.

What excipient opportunities exist for a Sumavel DosePro follow-on product?

The strongest opportunities are incremental. A competing product is unlikely to create substantial value through an entirely new excipient platform because the reference product already uses a simple solution.

Buffer and pH optimization

A new formulation could evaluate citrate, phosphate, acetate, or other low-concentration buffering systems. The commercial objective would be to improve:

• Long-term chemical stability.
• Resistance to pH drift.
• Compatibility with the injector and primary container.
• Stability under temperature excursions.
• Reduction of degradants formed during terminal sterilization or storage.

The risk is that added buffer capacity can alter osmolality, injection force, precipitation behavior, or tolerability. The formulation must also remain suitable for a small-volume subcutaneous injection.

Tonicity adjustment

Sodium chloride is a low-cost and familiar tonicity agent. Alternatives such as dextrose or other osmotic modifiers could be evaluated, but substitution would offer limited commercial differentiation unless it improves stability or injection tolerability.

For a 0.5 mL product, the excipient cost is unlikely to determine market success. The value would come from lower reject rates, better shelf life, reduced device failures, or easier regulatory bridging.

Container and device compatibility

The highest-value excipient-adjacent work concerns interaction between the formulation and the delivery system. Development teams should assess:

• Silicone oil or lubricant migration.
• Metal ion contamination.
• Elastomer extractables.
• Adsorption to polymeric components.
• Closure integrity.
• Particulate generation after device actuation.
• Compatibility with high-pressure fluid delivery.
• Changes in viscosity or surface tension that affect jet formation.

Needle-free systems can be more sensitive than conventional prefilled syringes because the formulation must generate a consistent fluid jet through a small orifice. A formulation that is acceptable in a syringe may not deliver consistently in a pressure-driven device.

Preservative-free multidose alternatives

A multidose product could use a preservative system, but this would change the risk profile. Sumavel DosePro’s single-use configuration avoids preservative tolerability issues and reduces microbial-risk complexity after opening.

A multidose presentation could lower packaging cost per dose, but it would face greater regulatory and usability burdens. It would also weaken the commercial similarity to the original single-use product.

Dry-powder or reconstitution products

A lyophilized or dry-powder sumatriptan product could improve certain stability characteristics, but it would add reconstitution steps and packaging complexity. That approach is poorly aligned with the original product’s principal advantage: rapid, simple, needle-free administration.

How does Sumavel DosePro compare with other sumatriptan products?

Sumavel DosePro competed primarily on delivery convenience and speed rather than on formulation composition.

Product type	Typical commercial advantage	Main limitation
Sumavel DosePro	Needle-free subcutaneous delivery	Device cost and training
Conventional sumatriptan vial	Low product cost	Requires syringe and needle
Sumatriptan prefilled syringe	Simplified injection	Needle exposure and injection anxiety
Sumatriptan autoinjector	Automated administration	Higher device cost
Sumatriptan nasal spray	No injection	Variable nasal absorption and sensory effects
Oral sumatriptan	Low cost and broad familiarity	Slower or less reliable absorption during nausea

The relevant comparator for a follow-on product is not only another sumatriptan formulation. It is the full treatment system, including injector, packaging, patient instructions, pharmacy handling, and reimbursement.

A lower-cost autoinjector or prefilled syringe may capture much of the same patient population without reproducing the needle-free mechanism. A true DosePro-style product would need to show that its device reduces pain, needle anxiety, administration time, or training burden enough to justify a premium.

What patents protect Sumavel DosePro?

The principal intellectual-property value was associated with the needle-free delivery technology and device configuration rather than the basic sumatriptan solution.

IP category	Commercial relevance
Sumatriptan active ingredient	No meaningful current exclusivity value; long-established small molecule
Basic aqueous formulation	Limited protection potential because of conventional excipients
Needle-free injector	Central historical differentiation
Cartridge and container closure	Potential device and combination-product protection
Actuation and fluid-jet mechanism	Potentially important device claims
Manufacturing process	Possible barrier if process-specific and difficult to design around
Method of use	Potential protection for migraine or cluster-headache dosing, subject to claim scope and expiry

Patent protection for the original product would need to be separated into Orange Book-listed drug patents, device patents, and unlisted platform patents. The FDA Orange Book is the controlling source for patents listed against the approved NDA, while USPTO records and litigation dockets are needed to assess broader device rights.[2,3]

The basic formulation has weak defensive characteristics because sodium chloride, water for injection, and pH adjustment are conventional choices. A follow-on company could likely design around formulation claims by changing buffer composition, concentration, container materials, or device architecture, provided it maintains bioequivalence and product performance.

What is the Orange Book status of Sumavel DosePro?

Sumavel DosePro was approved under NDA 022157. The commercial status of the product has changed since launch, and a current Orange Book review is required to determine whether the NDA remains listed as approved, discontinued, or otherwise subject to a current reference-product designation.[2]

The key diligence point is that an Orange Book listing would not automatically block a nonidentical needle-free injector. Product-level patents and platform-level device patents can have different owners, expiration dates, claim scopes, and enforcement histories.

When did Sumavel DosePro lose exclusivity?

The principal new-drug exclusivity period for a 2009 small-molecule approval would have expired years ago. Any remaining commercial barrier would therefore depend on patent claims, regulatory requirements, device similarity, manufacturing capability, and market economics rather than FDA chemical exclusivity.

The relevant timeline is:

Event	Timing
FDA approval under NDA 022157	2009
New chemical entity exclusivity	Expired during the early 2010s
Broad sumatriptan molecule exclusivity	Expired before Sumavel DosePro commercialization
Potential formulation or device patents	Dependent on individual filing and patent-term dates
Commercial discontinuation	Product is no longer a meaningful originator revenue contributor

No biosimilar pathway applies. Sumatriptan is a synthetic small molecule, so competitive entrants would use an ANDA, a 505(b)(2) application, or a full NDA strategy, not a biosimilar application.

What generic entry risks exist for Sumavel DosePro?

Generic-entry risk is high for the active ingredient and conventional injectable formulation, but lower for a direct needle-free replacement because the device creates additional technical and regulatory barriers.

505(j) ANDA pathway

A conventional sumatriptan succinate injection could pursue an ANDA if it matches the reference product’s active ingredient, strength, dosage form, route, and relevant performance characteristics. A product using a different delivery device may require additional comparative evidence.

Potential regulatory issues include:

• Device performance and reliability.
• Delivered-volume consistency.
• Drug-device combination-product requirements.
• Human-factors validation.
• Injection depth and dispersion.
• In-use stability.
• Container-closure integrity.
• Comparative pharmacokinetics.
• Local tolerability.

Paragraph IV challenges

A Paragraph IV certification could target any unexpired Orange Book patent listed for the NDA. The practical value of such a challenge depends on whether the asserted patent covers:

• The sumatriptan composition.
• The injector.
• The cartridge.
• The method of administration.
• A specific formulation or concentration.

A generic company may avoid device claims by commercializing a conventional syringe or autoinjector. That strategy would reduce patent exposure but also reduce product differentiation.

Which companies are challenging or competing with Sumavel DosePro?

The commercial competitive set includes manufacturers of generic sumatriptan injection, branded and generic sumatriptan nasal products, and other rapid-acting migraine therapies.

Relevant competitors include:

• Teva Pharmaceutical Industries.
• Sandoz and other generic manufacturers.
• GlaxoSmithKline historically, through the Imitrex franchise.
• Manufacturers of sumatriptan autoinjectors and prefilled syringes.
• Newer migraine companies commercializing gepants and CGRP-directed products.

The strongest competitive threat is not a direct copy of the DosePro injector. It is a lower-cost sumatriptan product delivered through a familiar syringe or autoinjector, combined with the expanding use of oral gepants and other non-triptan therapies.

What licensing deals affected Sumavel DosePro?

Zogenix commercialized Sumavel DosePro using its DosePro needle-free delivery platform. Public company filings described the platform as involving licensed or acquired technology and intellectual property associated with needle-free injection.[4]

The commercial importance of platform licensing is substantial. A follow-on developer would need to determine whether it can:

• License an existing needle-free injector.
• Acquire a platform from a device company.
• Develop a design-around injector.
• Use a conventional autoinjector and abandon the needle-free claim.
• Secure freedom to operate across the actuator, cartridge, nozzle, and container system.

The formulation itself is unlikely to require a high-value license. Device freedom to operate is the more important transaction issue.

How strong is the patent estate for Sumavel DosePro?

The estate is best characterized as moderate historically and weak for the basic formulation today.

Estate component	Strength assessment
Sumatriptan molecule	Weak or expired
Conventional aqueous solution	Weak
Specific excipient combination	Potentially narrow
Needle-free injector	Historically stronger
Device-fluid interface	Potentially meaningful
Manufacturing know-how	Moderate if trade-secret dependent
Method-of-use claims	Variable and indication-dependent
Biosimilar barriers	Not applicable

A durable competitive position would require a layered estate covering the injector architecture, fluid path, cartridge, actuation sequence, use instructions, and clinically relevant performance attributes. A single formulation patent would not provide comparable protection.

What manufacturing and IP barriers affect a new product?

The key manufacturing barrier is not sterile compounding alone. It is the integrated production of a reliable, low-cost drug-device system.

Critical capabilities include:

• Aseptic filling into device-compatible cartridges.
• High-volume assembly.
• Consistent nozzle dimensions.
• Actuator-force control.
• Device calibration.
• Container-closure testing.
• Particulate and extractables control.
• Human-factors packaging.
• Stability testing under shipping stress.
• Quality systems covering both drug and device manufacturing.

A conventional prefilled syringe can use established contract manufacturing capacity. A needle-free injector requires specialized tooling, assembly, testing, and supplier qualification. That difference can determine whether a product reaches the market at a competitive price.

What commercial opportunities remain?

The most attractive opportunities are:

1. A lower-cost needle-free sumatriptan injector for patients who avoid needles.
2. A compact autoinjector with fewer preparation steps.
3. A preservative-free single-dose presentation with improved shelf life.
4. A hospital or urgent-care presentation optimized for rapid administration.
5. A co-packaged migraine rescue product with clear patient training.
6. A 505(b)(2) product using a differentiated delivery system or formulation.
7. A licensing deal involving a proven injector platform and an established sterile manufacturer.

The least attractive opportunity is a minor excipient substitution with no measurable improvement in stability, tolerability, device function, or cost. Sodium chloride replacement alone is unlikely to create defensible value.

Key Takeaways

• Sumavel DosePro used a simple aqueous sumatriptan formulation with sodium chloride, water for injection, and pH adjustment.
• Its differentiation came from a single-use, needle-free injector, not from a novel excipient system.
• The formulation is relatively easy to design around; the device and drug-device interface are more defensible.
• FDA chemical exclusivity is long expired, and biosimilar risk is irrelevant because sumatriptan is a small molecule.
• A conventional generic injection faces high competition, while a direct needle-free replacement faces higher technical and device-IP barriers.
• The strongest commercial opportunity is a lower-cost, reliable delivery system supported by stability, human-factors, and manufacturing advantages.
• The primary diligence issues are current Orange Book status, unexpired device patents, freedom to operate, and commercial feasibility of the injector.

FAQs

Can a competitor copy Sumavel DosePro using the same excipients?

Yes, subject to regulatory equivalence, patent clearance, and device compatibility. The excipient system is conventional and unlikely to provide broad protection by itself.

Is a new Sumavel DosePro product eligible for a 505(b)(2) application?

Potentially. A differentiated delivery device, formulation, or route-related presentation could support a 505(b)(2) strategy, depending on the extent of reliance on the listed drug and the evidence required by FDA.

Would a generic sumatriptan syringe infringe Sumavel DosePro patents?

Not necessarily. A syringe may avoid patents directed specifically to the needle-free injector, cartridge, actuator, or jet-delivery mechanism. Infringement depends on the claims of each unexpired patent.

Are formulation patents more valuable than device patents for this product?

No. For Sumavel DosePro, device patents and drug-device interface claims are more commercially important than claims covering sodium chloride, water, and pH adjustment.

Could a preservative-free autoinjector replace Sumavel DosePro?

Yes. A preservative-free, single-dose autoinjector could address many of the same patients while using a more established delivery platform. Its commercial success would depend on device cost, usability, reimbursement, and differentiation from generic sumatriptan injections.

References

1. U.S. Food and Drug Administration. (2009). Sumavel DosePro (sumatriptan injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System.
4. Zogenix, Inc. (2012). Annual report on Form 10-K for the fiscal year ended December 31, 2011. U.S. Securities and Exchange Commission.